AI In Silico Multi-Omics Technique Cuts Therapeutic Development Costs
GATC Health says that an AI-driven in silico multi-omics approach shaves time off preclinical development by derisking programs early-on and expanding opportunities. The post AI <i>In Silico</i> Multi-Omics Technique Cuts Therapeutic Development Costs appeared first on GEN - Genetic Engineering and Biotechnology News .
The pharmaceutical industry has long struggled with the high costs and lengthy timelines associated with bringing new drugs to market. Preclinical development alone can cost between $15 million and $100 million, a significant burden on companies seeking to develop innovative therapies. However, the integration of artificial intelligence (AI) into the drug discovery process is beginning to change the landscape, offering a pathway to reduce costs and accelerate development.
GATC Health, an AI-driven therapeutic discovery company, has developed an in silico multi-omics approach that leverages AI to streamline preclinical development. This technique, which combines advanced computational models with a multi-omics analysis, aims to derisk programs early on and identify high-potential compounds more efficiently. According to Jayson Uffens, CTO and chairman of GATC Health, the use of AI in the early stages of drug development can lead to significant cost savings and faster progression towards clinical trials.
Uffens emphasizes that AI is not a silver bullet, but rather a tool that enhances the capabilities of human experts. He states, "Smart computing makes smart people smarter. There's still a lot of expertise from people on the ground who bring a lot of valueтАФmaybe the ultimate valueтАФto the mix." GATC Health's proprietary approach to hit and lead identification, powered by its AI platform Operon, enables the company to deliver three to five optimized compounds within six months, compared to the traditional high-throughput screening methods that can take up to 48 months.
Operon's in silico models simulate human biology and analyze data from multiple omics layers, such as genomics, transcriptomics, and proteomics. This multi-faceted approach allows the company to bypass the need for extensive experimental work, which can be costly and time-consuming. Uffens explains, "We attack the problem from multiple facets, looking at individual problems with various models and different architectures... and coordinate hundreds of AI models to answer different questions. That's the starting point. There's a lot of value in how we curate and parameterize our data in those specific contexts."
In addition to its in silico multi-omics platform, GATC Health has also launched the Derisq AI Report, an in-depth analysis of drug candidates that combines AI-driven insights with expert human judgment. This report provides a comprehensive evaluation of potential therapeutic targets and helps companies make informed decisions about their drug development pipelines.
The success of GATC Health's AI-driven approach highlights the potential of leveraging advanced computational methods to transform the drug discovery process. By using AI to identify promising compounds earlier and more efficiently, the company is not only reducing preclinical development costs but also accelerating the path to clinical trials. As the pharmaceutical industry continues to grapple with the challenges of high costs and long timelines, the integration of AI into drug development offers a promising solution to unlock new therapeutic opportunities and drive innovation in the field.
